Keywords: eisai/pfizer, aricept, improves, ad, hispanics, japanese, drugmaker
Eisai/Pfizer's Aricept improves AD in Hispanics
Article | 11 August 2008
Japanese drugmaker Eisai and USA-based Pfizer have presented results from an open-label study showing that Hispanics with mild-to-moderate Alzheimer's disease ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
